MIR1206: MIR1206 is a microRNA that is encoded by the PVT1 gene and has been reported to exhibit oncogenic properties [PMC9191314]. PVT1 generates a diverse assortment of alternatively spliced RNAs as well as multiple microRNAs, including MIR1206 [PMC6160183]. The MYC gene breakpoints were mapped to the PVT1 locus that harbors MIR1206 [PMC2739276]. Coamplification of MYC and PVT1 has been shown to correlate with rapid progression of breast cancer and poor clinical survival [PMC6160183]. MIR1206 is part of a cluster of miRNAs within the PVT1 genomic DNA region, and its regulatory functions within the MYC-PVT1 locus are still being investigated [PMC4172193]. It has been suggested that MIR1206 may act as RNA interference, potentially connected to PAG1 [PMC7846894]. The MIR1206 rs2114358 AG-GG genotypes have shown a reduced risk of chronic lymphocytic leukemia (CLL) [PMC4368096]. This variant may alter the maturation and secondary structure of MIR1206, potentially affecting its function in cancer development [PMC4368096]. Overexpression of the PVT1 transcript, including MIR1206, has been observed in various tumor tissues [PMC4368096]. The chromosomal location of MIR1206 at 8q24.2 is frequently associated with cancer-related chromosomal breaks and genomic instability [PMC4368096]. In relation to gastric cancer (GC), rs2114358 in the precursor sequence of MIR1206 has shown an inverse association with non-cardia adenocarcinoma risk but not cardia adenocarcinoma risk. Additionally, other miRNA single nucleotide variants (SNVs) have also been associated with GC risk [PMC6687864]. In conclusion, MIR1206, encoded by the PVT1 gene, is a microRNA with potential oncogenic properties and is implicated in various cancers, including breast cancer, CLL, and GC [PMC9191314][PMC6160183][PMC2739276][PMC4172193][PMC7846894][PMC4368096][PMC6687864].